Intelligence Feed event · Policy · 2026-08-26

    FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor

    Question

    FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor

    Direct answer

    The U.S. Food and Drug Administration granted marketing approval to Revolution Medicines for RASONQUE (daraxonrasib). The drug is authorized for patients with metastatic pancreatic adenocarcinoma who progressed on prior therapy or cannot tolerate multiagent chemotherapy. The regulatory clearance marks a significant milestone in oncology by establishing the first commercial broad RAS-targeted inhibitor, validating the company's RAS(ON) inhibitor pipeline.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-26
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor”, revision 1, evidence through 2026-08-26. https://marketontology.com/market-events/2026-08-26/fda-approves-revolution-medicines-rasonque-as-first-targeted-ras-inhibitor-04fdcd

    POLICY
    FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor
    The U.S. Food and Drug Administration granted marketing approval to Revolution Medicines for RASONQUE (daraxonrasib). The drug is authorized for patients with metastatic pancreatic adenocarcinoma who progressed on prior therapy or cannot tolerate multiagent chemotherapy. The regulatory clearance marks a significant milestone in oncology by establishing the first commercial broad RAS-targeted inhibitor, validating the company's RAS(ON) inhibitor pipeline.
    RVMDXBI
    Impact
    73
    AUG 26
    SIG
    92%
    RVMDXBI
    FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor
    The U.S. Food and Drug Administration granted marketing approval to Revolution Medicines for RASONQUE (daraxonrasib). The drug is authorized for patients with metastatic pancreatic adenocarcinoma who progressed on prior therapy or cannot tolerate multiagent chemotherapy. The regulatory clearance marks a significant milestone in oncology by establishing the first commercial broad RAS-targeted inhibitor, validating the company's RAS(ON) inhibitor pipeline.
    → Regulatory approval transitions Revolution Medicines into commercial-stage oncology revenue generation, expanding the addressable market for targeted KRAS and RAS therapies.
    Impact
    The U.S. Food and Drug Administration granted marketing approval to Revolution Medicines for RASONQUE (daraxonrasib). The drug is authorized for patients with metastatic pancreatic adenocarcinoma who progressed on prior therapy or cannot tolerate multiagent chemotherapy. The regulatory clearance marks a significant milestone in oncology by establishing the first commercial broad RAS-targeted inhibitor, validating the company's RAS(ON) inhibitor pipeline.
    Affected
    RVMDXBI
    Transmission
    Regulatory approval transitions Revolution Medicines into commercial-stage oncology revenue generation, expanding the addressable market for targeted KRAS and RAS therapies.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDcommercial product revenue launch and addressable market captureUp1-4wFDA approved Revolution Medicines' RASONQUE as first targeted RAS medicine in metastatic pancreatic cancer.
    XBIbiotech clinical and regulatory sentiment transmissionUp1-5dFDA approval validates novel targeted oncology mechanism in clinical pipeline.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XBIUpdisagreed168.39 2026-08-26-0.10%-1.79%-7.33%

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month